SCHEMBL898657

SCHEMBL898657

CC1(C)OC(=O)C(=C(O)Cc2cc(F)c(F)cc2F)C(=O)O1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.44
CDC25B P30305 5/20 0.44
ACP1 P24666 4/20 0.44
ALDH1A1 P00352 5/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TSHR P16473 1/20 0.31
HCAR3 P49019 2/20 0.31
HCAR2 Q8TDS4 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30
MMP12 P39900 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30167913 1.00 PTPN1 (0.44) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2
SCHEMBL26076653 0.93 PTPN1 (0.47) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2
SCHEMBL21428297 0.86 PTPN1 (0.41) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2
SCHEMBL8307611 0.84 PTPN1 (0.41) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2
SCHEMBL3722145 0.82 PTPN1 (0.38) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2
SCHEMBL15304876 0.82 PTPN1 (0.40) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2
SCHEMBL31551715 0.79 PTPN1 (0.42) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2
SCHEMBL19510006 0.79
SCHEMBL25634579 0.78 PTPN1 (0.32) PTPN1
SCHEMBL12027602 0.76 RIPK1 (0.36) PTPN1CDC25BACP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115583935-A Preparation method of 4- (2, 4, 5-trifluorophenyl) -3-oxybutyrate ester 浙江工业大学 2023-01-10 CN claimed
WO-2010122578-A2 PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES MSN LABORATORIES LIMITED (IN) 2010-10-28 WO claimed
WO-2023175492-A1 NOVEL INTERMEDIATES AND ITS USE IN MANUFACTURING OF SITAGLIPTIN HIKAL LIMITED (IN) 2023-09-21 WO disclosed
US-20230174461-A1 METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2023-06-08 US disclosed
US-20230174461-A1 METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2023-06-08 US disclosed
CN-112341332-B Recycling method of sitagliptin key intermediate degradation waste 浙江昌明药业有限公司 2023-04-28 CN disclosed
CN-115583935-A Preparation method of 4- (2, 4, 5-trifluorophenyl) -3-oxybutyrate ester 浙江工业大学 2023-01-10 CN disclosed
CN-115583935-A Preparation method of 4- (2, 4, 5-trifluorophenyl) -3-oxybutyrate ester 浙江工业大学 2023-01-10 CN disclosed
CN-113666904-A Preparation method of sitagliptin phosphate intermediate 浙江医药股份有限公司新昌制药厂 2021-11-19 CN disclosed
US-11174266-B2 Efficient process for the preparation of sitagliptin F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2021-11-16 US disclosed
CN-113636950-A Preparation method of chiral 4-aryl-beta-amino acid derivative 浙江医药股份有限公司新昌制药厂 2021-11-12 CN disclosed
WO-2006104997-A2 TARTARIC ACID SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK & CO., INC. (US) 2006-10-05 WO disclosed
WO-2006065826-A2 PROCESS TO CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION MERCK & CO., INC. (US) 2006-06-22 WO disclosed
WO-2006033848-A1 AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK & CO., INC. (US) 2006-03-30 WO disclosed
WO-2005072530-A1 NOVEL CRYSTALLINE SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK & CO., INC. (US) 2005-08-11 WO disclosed
WO-2005030127-A2 NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK & CO., INC. (US) 2005-04-07 WO disclosed
WO-2005020920-A2 NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK & CO., INC. (US) 2005-03-10 WO disclosed
WO-2005003135-A1 PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK & CO., INC. (US) 2005-01-13 WO disclosed
WO-2004085661-A2 PROCESS TO CHIRAL BETA-AMINO ACID DERIVATIVES MERCK & CO., INC (US) 2004-10-07 WO disclosed
WO-2004085378-A1 PROCESS FOR THE PREPARATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION MERCK & CO. INC. (US) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174461-A1 METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE ENPEP, BCAT2, BCAT1 PTPN1 4607/4885CDC25B 2785/4885ACP1 996/4885
US-11174266-B2 Efficient process for the preparation of sitagliptin DPP4, DPP9, DPP7 PTPN1 1130/4885CDC25B 3609/4885ACP1 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.